Source comparison
SS-31 Dosage Mitochondrial Function 2026: Protocol Comparison
Acute ischemia (cardiac, renal, CNS) 3–5mg/kg IV bolus Single dose pre-injury 40–60% reduction in tissue necrosis vs control Timing trumps dose. Administer 30–60 min before anticipated oxidative event Neurodegenerative models (chronic) 0.5–1mg/kg SC Twice dail
This comparison does not assign a generated winner or score.
- Acute ischemia (cardiac, renal, CNS)
- 3–5mg/kg
- IV bolus
- Single dose pre-injury
- 40–60% reduction in tissue necrosis vs control
- Timing trumps dose. Administer 30–60 min before anticipated oxidative event
- Neurodegenerative models (chronic)
- 0.5–1mg/kg
- SC
- Twice daily
- Preserved motor function, reduced ROS markers
- Low-dose frequent beats high-dose sporadic for sustained neuroprotection
- Metabolic / age-related dysfunction
- 3mg/kg
- Once daily
- Restored mitochondrial respiration, improved exercise capacity
- 8+ weeks required for functional outcomes. Single-dose studies show mechanism only
- Barth syndrome / cardiolipin deficiency
- 40mg (fixed) or 4mg/kg
- SC or IV
- Improved LV stroke volume, reduced NT-proBNP
- High cardiolipin-density tissues respond to higher doses; skeletal muscle does not
- Sepsis / ARDS models
- 5mg/kg
- IV
- Single or q12h × 3 days
- Reduced organ failure scores, improved survival
- Acute high-dose outperforms chronic low-dose in cytokine storm contexts